Aspen Aerogels (NYSE: ASPN) reported Q4 EPS of ($0.20), $0.10 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $59.6 million versus the consensus estimate of $50.59 million.

GUIDANCE:

Aspen Aerogels sees FY2023 EPS of ($1.31)-($1.46), versus the consensus of ($1.04). Aspen Aerogels sees FY2023 revenue of $200-250 million, versus the consensus of $243.7 million.

For earnings history and earnings-related data on Aspen Aerogels (ASPN) click here.